Britain is paying to fix the front of the dementia pathway, and a blood test is the commercial prize among the nine projects.
The average cut is 16%. The tests carrying the newest science take the deepest cuts, and proprietary ones barely move.
The census counts publicly registered evidence, so it measures disclosure. Without a non-AI comparator it cannot show this is an AI problem.
The approach came in 2017 as Philips prepared to close the plant. A site closure is a knowledge event before it is a cost event.
Most of the guideline concerns where ctDNA should not be used. The application carrying the largest commercial expectations got no recommendation.
A three-way result means some patients resolve neither way, and those still go to imaging. Roche has not said how many land in the middle.
The order moves these tests from PMA to 510(k). One special control was deleted, and the predicate chain is where the change compounds.
Three glioblastoma patients returned identical MGMT results and behaved differently on a barrier chip. The sample size is three, and the framing still matters.
Freenome defined its population by the failure of the existing pathway, not by anything measurable in the patient. That is the decision worth reading.
Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.